TABLE 5.
Covariate | Before PS matching ‐ means | After PS matching ‐ means | ||||
---|---|---|---|---|---|---|
BRAF/MEKi | aPD‐1 | Standardized difference a | BRAF/MEKi | aPD‐1 | Standardized difference | |
Age at 1L initiation | 61.118638 | 62.893807 | 0.124 | 61.397791 | 62.630218 | 0.055 |
BMI at 1L initiation | 28.160065 | 28.091854 | 0.012 | 27.77051 | 27.504839 | 0.030 |
Deyo‐adapted Charlson Score | 1.1574803 | 1.3209877 | 0.103 | 1.0619455 | 1.2157635 | 0.074 |
Brain metastases | 0.3700787 | 0.2098765 | 0.359 | 0.3026492 | 0.282466 | 0.044 |
Lung metastases | 0.496063 | 0.2839506 | 0.446 | 0.4578971 | 0.4458166 | 0.024 |
Liver metastases | 0.3070866 | 0.0864198 | 0.578 | 0.2198274 | 0.20815 | 0.028 |
Bone metastases | 0.2992126 | 0.2098765 | 0.206 | 0.3089958 | 0.3113862 | 0.005 |
Other metastases | 0.7322835 | 0.5555556 | 0.376 | 0.6873984 | 0.639114 | 0.102 |
ECOG performance status 0‐1 | 0.5826772 | 0.7530864 | 0.368 | 0.6058463 | 0.5896688 | 0.033 |
ECOG performance status 2+ | 0.2204724 | 0.0493827 | 0.517 | 0.1523432 | 0.1494931 | 0.008 |
ECOG performance status not documented | 0.1968504 | 0.1975309 | 0.002 | 0.2418106 | 0.2608381 | 0.044 |
Stage at diagnosis III/IV | 0.8267717 | 0.6296296 | 0.454 | 0.7199062 | 0.721749 | 0.004 |
Stage at diagnosis I/II | 0.0866142 | 0.0740741 | 0.046 | 0.0767331 | 0.0789891 | 0.008 |
Stage at diagnosis not documented | 0.0866142 | 0.2962963 | 0.553 | 0.2033607 | 0.1992619 | 0.010 |
Albumin result – low | 0.3464567 | 0.1481481 | 0.472 | 0.2714096 | 0.2513166 | 0.046 |
Albumin result – normal | 0.503937 | 0.7901235 | 0.628 | 0.6100672 | 0.632766 | 0.047 |
Albumin result ‐ not documented | 0.1496063 | 0.0617284 | 0.289 | 0.1185232 | 0.1159174 | 0.008 |
Female | 0.3543307 | 0.382716 | 0.059 | 0.3917868 | 0.3827421 | 0.019 |
Practice region ‐ South | 0.5669291 | 0.5432099 | 0.048 | 0.5134602 | 0.5636567 | 0.101 |
Practice region ‐ West | 0.3149606 | 0.2716049 | 0.095 | 0.2924953 | 0.2746459 | 0.040 |
Practice region ‐ Midwest | 0.0708661 | 0.1111111 | 0.140 | 0.1267328 | 0.0757432 | 0.170 |
Practice region ‐ Northeast | 0.0472441 | 0.0740741 | 0.113 | 0.0673117 | 0.0859542 | 0.070 |
Prior radiation | 0.3700787 | 0.3703704 | 0.001 | 0.3939133 | 0.4177884 | 0.049 |
Prior surgery | 0.6614173 | 0.7530864 | 0.202 | 0.7084217 | 0.711024 | 0.006 |
LDH result ‐ normal | 0.3700787 | 0.5061728 | 0.277 | 0.4089619 | 0.3629776 | 0.095 |
LDH result ‐ elevated | 0.2519685 | 0.1851852 | 0.162 | 0.2306331 | 0.2646264 | 0.079 |
LDH result ‐ not documented | 0.3779528 | 0.308642 | 0.146 | 0.360405 | 0.372396 | 0.025 |
History of tobacco exposure | 0.488189 | 0.5185185 | 0.061 | 0.5264428 | 0.5011438 | 0.051 |
History of tobacco exposure ‐ not documented | 0.015748 | 0.0246914 | 0.064 | 0.0144088 | 0.0162188 | 0.015 |
Abbreviations: 1L, first‐line; aPD‐1, anti‐PD‐1 monotherapies; BMI, body mass index; BRAF/MEKi, BRAF/MEK inhibitors; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
Any standardized difference of more than 0.2 suggests an balanced between the two groups.